



Bijen, H. M., van der Steen, D. M., Hagedoorn, R. S., Wouters, A. K., Wooldridge, L., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2018). Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs. *Molecular Therapy*, 26(5), 1206-1214.
<https://doi.org/10.1016/j.ymthe.2018.02.017>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.ymthe.2018.02.017](https://doi.org/10.1016/j.ymthe.2018.02.017)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier (Cell Press) at <https://www.sciencedirect.com/science/article/pii/S1525001618300704> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms>

Preclinical strategies to identify off-target toxicity of high-affinity TCRs

Helena M. Bijen¹, Dirk M. van der Steen¹, Renate S. Hagedoorn¹, Anne K. Wouters¹, Linda Wooldridge², J. H. Frederik Falkenburg¹, Mirjam H.M. Heemskerk¹

¹ Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

² Faculty of Health Sciences, University of Bristol, Biomedical Sciences Building, Bristol, UK

Correspondence should be addressed to Mirjam H.M. Heemskerk (PhD):

Leiden University Medical Center

Department of Hematology

C2-R, P.O. Box 9600

2300 RC Leiden

The Netherlands

31-71-5262271 (secre) / 63207 (room nr)

M.H.M.Heemskerk@lumc.nl

Short title: Strategies to identify off-target TCR toxicities

Abstract

Adoptive transfer of T-cells engineered with a cancer specific T-cell receptor (TCR) have demonstrated clinical benefit. However, the risk for off-target toxicity of TCRs remains a concern.

Here, we examined the cross-reactive profile of T-cell clone (7B5) with a high functional sensitivity for the hematopoietic-restricted minor histocompatibility antigen HA-2 in the context of HLA-A*02:01. HA-2^{pos} EBV-LCLs and primary acute myeloid leukemia samples, but not hematopoietic HA-2^{neg} samples, are effectively recognized. However, we found unexpected off-target recognition of human fibroblasts and keratinocytes not expressing the HA-2 antigen.

To uncover the origin of this off-target recognition we performed an alanine scanning approach, identifying 6 out of 9 positions to be important for peptide recognition. This indicates a low risk for broad cross-reactivity. However, using a combinatorial peptide library scanning approach, we identified a *CDH13* derived peptide activating the 7B5 T-cell clone. This was confirmed by recognition of *CDH13*-transduced EBV-LCLs and cell subsets endogenously expressing *CDH13*, such as proximal tubular epithelial cells.

As such, we recommend the use of a combinatorial peptide library scan followed by screening against additional cell subsets to validate TCR specificity and detect off-target toxicity due to cross-reactivity directed against unrelated peptides before selecting candidate TCRs for clinical testing.

Introduction

Immunotherapy has obtained a prominent role in the field of oncology and has proven valuable in the treatment of different types of tumors. A range of immunotherapies are under development, varying from chimeric antigen receptors (CARs)¹, expanding tumor infiltrating lymphocytes (TILs)^{2,3} and TCR transduced effector cells^{4,5}. Various studies successfully make use of TCR-engineered T-cells to enhance patients adaptive immune responses against malignancies, demonstrating potent anti-tumor reactivity⁶⁻⁹.

No matter how promising therapies using TCR-engineered T-cells may be, they come with side effects and risks. T-cells are naturally checked for recognition of self-peptides in the context of self-HLA and deleted in the thymus if this recognition is too strong, in a process called negative selection¹⁰. This selection process is absent or non-optimal when TCRs are derived from donors with mismatched HLA-typing, when they are isolated from humanized mouse models expressing only one HLA molecule and no human proteins, or when TCRs are structurally altered for affinity enhancement^{11,12}.

Affinity enhancement of TCRs can result in both on- and off-target toxicity¹³. Recent examples of clinically tested TCRs directed against MAGE-A3 and MART-1 demonstrated severe toxicities^{12,14-17}. In the clinical trial testing a modified anti-MAGE-A3 TCR, derived from immunization of HLA-A*02:01 transgenic mice, 2 out of 9 cancer patients developed fatal on-target neurological toxicity, due to recognition of a peptide derived from the same gene-family which is expressed in the brain¹⁵. In another trial, where an affinity enhanced anti-MAGE-A3 TCR was tested in myeloma and melanoma patients, 2 patients died due to off-target toxicity caused by recognition of a completely different peptide, resulting in severe myocardial damage^{12,17}. These clinical cases show how difficult it is to predict the exact specificity and the resulting

effects of TCRs that did not undergo optimal thymic selection. It is crucial to develop strategies to extensively validate the exact specificity of TCRs, particularly since TCR-engineered T-cells are highly sensitive^{14, 18}.

In this study, we aimed to develop a reliable screening pipeline for early detection of off-target toxicity due to the cross-reactivity of TCRs directed against unrelated peptides. In previous work, we have focused on the identification of therapeutic TCRs directed against hematopoietic restricted minor histocompatibility antigens (MiHA) for the treatment of hematological malignancies. The HLA-A*02:01 restricted HA-2 peptide YIGEVLVSV is a well-known example of such a MiHA^{19, 20}. In recent experiments we isolated a HA-2 specific T-cell clone, 7B5, using an *in vitro* HLA-mismatched setting. We validated its specificity for the HA-2 antigen in hematopoietic cell subsets. However, we found unexpected off-target recognition of human fibroblasts not expressing the HA-2 antigen, raising the questions what triggered this activation and what method is suitable to examine this. Thus, we investigated the off-target cross-reactive potential of this high avidity T-cell clone using different screening methods and characterized its fine specificity.

Currently, an amino acid scanning approach is the recommended method²¹, which we compared to screening with a 9-mer combinatorial peptide library (CPL)²². To validate recognition of predicted cross-reactive target peptides by the 7B5 T-cell clone, as discovered by the different screening approaches, we then screened the 7B5 T-cell clone against several non-hematopoietic cell subsets endogenously expressing these peptides. As a control, we used a HA-2 specific T-cell clone, HA2.27, previously isolated from a chronic myeloid leukemia patient that experienced a Graft versus Leukemia (GvL) response after HLA-matched SCT and subsequent

donor lymphocyte infusion (DLI)²³. The patient from whom these clones were isolated did not experience any harmful GvHD²⁴ and no *ex vivo* cross-reactivity was discovered.

We show that the amino acid scanning approach alone provided useful information about which amino acid (AA) positions in the peptide are important for TCR recognition, but its ability to elucidate the cross-reactivity profile of the 7B5 TCR was limited. Instead, we were able to detect off-target reactivity directed against a peptide derived from *CDH13* using a CPL scanning approach. This was confirmed with *CDH13* transduced HA-2^{neg} EBV-LCLs and the potential *in vivo* consequences were deduced by screening against a broad range of different cell subsets.

Results

Identification of a HA-2 specific T-cell clone from the allogeneic TCR repertoire

T-cell clones from an HLA-A*02:01^{neg} individual were isolated using pMHC-tetramers composed of the HA-2 peptide bound to HLA-A*02:01. pMHC-tetramer^{pos} cells were first enriched by magnetic-activated cell sorting (MACS) followed by single-cell sorting of pMHC-tetramer^{pos} CD8^{pos} T-cells. T-cell clones were selected that demonstrated reactivity against T2 cells loaded with the HA-2 peptide but not against unloaded T2 cells. Among these T-cell clones, clone 7B5 demonstrated the highest functional sensitivity when stimulated with titrated amounts of HA-2 peptide. This reactivity was comparable to the patient derived control clone HA2.27, that was isolated from a beneficial GVL response after allogeneic stem cell transplantation (SCT) and subsequent DLI (*Figure 1A*).

Specific binding to the APC-labeled HA-2 pMHC-tetramer was validated for both T-cell clones. Both the 7B5 T-cell clone and the HA2.27 T-cell clone showed specific staining with the APC-labeled HA-2 pMHC-tetramer with similar intensity (*Figure 1B*).

Expression of the *MYO1G* gene, encoding for the MiHA HA-2, is restricted to hematopoietic tissues²⁰. We confirmed this restricted expression in an in-house generated microarray gene expression database (*Supplementary Figure 1*)²⁵. To investigate whether T-cell clone 7B5 was able to selectively recognize cell subsets expressing HA-2 we tested the HA-2 reactive T-cell clones against different hematopoietic cell subsets, starting with SNP-genotyped EBV-LCLs that were either positive or negative for the MiHA HA-2. Robust recognition of HLA-A*02:01^{pos} HA-2^{pos} EBV-LCLs, but not HLA-A*02:01^{pos} HA-2^{neg} or HLA-A*02:01^{neg} EBV-LCLs was detected, which was comparable to the HA2.27 T-cell clone (*Figure 2A*). In addition, the anti-tumor reactivity of T-cell clone 7B5 was tested against different HLA-A*02:01^{pos} primary AML samples either positive or negative for the MiHA HA-2. HLA-A*02:01^{pos} fibroblasts and HLA-A*02:01^{pos} keratinocytes were included as HA-2^{neg} controls. HA-2^{pos} AML samples were similarly recognized by both the HA2.27 T-cell clone and the 7B5 T-cell clone, whereas the HA-2^{neg} AML sample was not (*Figure 2B*). However, the HLA-A*02:01^{pos} HA-2^{neg} fibroblasts and keratinocytes that were not recognized by the HA2.27 T-cell clone as expected, were efficiently recognized by the 7B5 T-cell clone (*Figure 2B*).

All these results indicate that the 7B5 T-cell clone is a high avidity T-cell clone, capable of targeting HA-2 expressing hematopoietic cell subsets in the context of HLA-A*02:01.

Unexpectedly, the 7B5 T-cell clone recognized HLA-A*02:01^{pos} HA-2^{neg} human fibroblasts and keratinocytes as well.

Analysis of off-target cross-reactivity of the 7B5 T-cell clone

We showed that the 7B5 T-cell clone and the HA2.27 T-cell clone have a similar functional sensitivity for HA-2, but the 7B5 T-cell clone demonstrated cross-reactivity against HA-2^{neg}

fibroblasts and keratinocytes. In order to assess what causes this off-target recognition of fibroblasts and keratinocytes we used an alanine scanning approach. Both HA-2 reactive clones were tested against the immunogenic HA-2 sequence (YIGEVLVSV), the naturally occurring non-immunogenic counterpart (YIGEVLVSM), and newly synthesized HA-2 peptides in which every AA is sequentially replaced by an alanine (A). In *Table 1* the different peptides are summarized. According to NetMHC4.0 none of the alanine substitutions interfere with HLA-A*02:01 binding to a relevant extent. Both HA-2 T-cell clones were incubated overnight with peptide-pulsed T2 cells at different concentrations (8 nM, 40 nM and 200 nM), and IFN- γ production was measured. When alanine substitution resulted in a substantial decrease in IFN- γ production compared to the immunogenic HA-2 sequence, this position was considered essential. The results, depicted in *Figure 3A-C*, demonstrate that for T-cell clone 7B5 positions 2, 3, 4, 5, 6 and 7 were important for HA-2 specific recognition. This recognition pattern was slightly different from the HA-2.27 clone, since for this clone positions 1, 2, 3, 4, and 6 were important for HA-2 specific recognition.

For the 7B5 T-cell clone an *in silico* search was carried out to identify protein sequences that contain the motif X-I-G-E-V-L-V-X-X. We searched for human self-protein derived peptide sequences with this motif using the ScanProsite webtool. Besides the HA-2 peptide, this search resulted in only one other peptide sequence PIGEVLVSS derived from the human gene KLF6. However, this KLF6 derived sequence was not predicted to bind HLA-A*02:01 according to NetMHC4.0, thus we concluded that there was a low risk of cross-reactivity, based on this amino acid scanning approach.

Next we performed a 9-mer combinatorial peptide library (CPL) scan. This CPL is composed of 180 different 9-mer peptide mixtures. In every peptide mixture one AA position has a fixed L-amino acid residue, but all other positions are degenerate enabling incorporation of any 1 of 19 natural L-amino acids in all remaining 8 positions (cysteine is excluded). The 7B5 T-cell clone was incubated overnight with T2 cells pulsed with the 180 different peptide mixtures and IFN- γ production was measured. Results are depicted in a heatmap (*Figure 4*). Using the WSBC PI CPL webtool, we conducted a 9-mer CPL-driven search of the human self-protein database to produce a list of the top 100 peptide sequences ranked in order of likelihood of recognition (*Supplementary Table 1*). After removing duplicate sequences a list of 42 peptide sequences remained and further refined on the basis of whether they were predicted to bind HLA-A*02:01 using NetMHC4.0. This resulted in a final list of 10 peptide sequences which were subsequently synthesized (*Table 2*). The ability of the T-cell clones 7B5 and HA2.27 to recognize these candidate peptides was determined by measuring the IFN- γ production after stimulation with T2 cells loaded with titrated concentrations of these peptides. Only one peptide, the *CDH13* derived peptide (p01) SVGSVLLTV, was recognized with a similar sensitivity as the HA-2 peptide (p02) (*Figure 5A*). The patient derived HA2.27 control clone did not recognize any other peptide but HA-2 (*Figure 5B*).

In order to confirm processing and presentation of the *CDH13* derived peptide in HLA-A*02:01, we transduced *CDH13* into two different HLA-A*02:01^{pos} HA-2^{neg} EBV-LCLs (IZA and HRK). Recognition of the transduced and untransduced EBV-LCLs was evaluated by IFN- γ ELISA. The 7B5 T-cell clone did not recognize untransduced HLA-A*02:01^{pos} HA-2^{neg} EBV-LCLs, similar to the HA2.27 T-cell clone, but *CDH13* transduced HLA-A*02:01^{pos} HA-2^{neg} EBV-LCLs were highly recognized by the 7B5 T-cell clone, whereas the HA2.27 T-cell clone was not able

to recognize these transduced EBV-LCLs (*Figure 5C*). These results demonstrate that T-cell clone 7B5 is cross-reactive against the *CDH13* derived peptide.

Cross-reactivity directed against CDH13

We showed that T-cell clone 7B5 is cross-reactive towards a *CDH13* derived peptide which is presented by HLA-A*02:01. Next, we wanted to investigate the possible implications of this cross-reactivity *in vivo*. According to our gene expression microarray database²⁵, the *CDH13* gene is expressed by a wide variety of healthy non-hematopoietic cell subsets, e.g. fibroblasts, keratinocytes, proximal tubular epithelial cells and melanoma cell line FM6 (*Supplementary Figure 2*). We tested the 7B5 T-cell clone against keratinocytes and fibroblasts derived from HLA-A*02:01^{pos} donors, either untreated or pretreated with IFN- γ for 2 days to upregulate HLA expression, and HLA-A*02:01^{pos} proximal tubular epithelial cells and melanoma cell line FM6. All cell-subsets were recognized by the 7B5 T-cell clone, but not by the HA2.27 T-cell clone (*Figure 6*). To confirm that only HLA-A*02:01 restricted epitopes were recognized, we included HLA-A*02:01^{neg} fibroblasts, either untreated or pretreated with IFN- γ for 2 days. The HLA-A*02:01^{neg} fibroblasts were unable to activate the 7B5 T-cell clone (*Figure 6*).

All these results demonstrate that the 7B5 T-cell clone can activate in response to both the HA-2 antigen and the *CDH13* derived peptide SVGSVLLTV, causing cross-reactivity restricted to HLA-A*02:01^{pos} tissues.

Discussion

In this study, we detected off-target reactivity of the 7B5 TCR directed against a peptide derived from the gene *CDH13* using a CPL scanning approach, which was confirmed by the ability of

the 7B5 T-cell clone to recognize *CDH13* transduced HA-2^{neg} EBV-LCLs and several cell subsets endogenously expressing *CDH13*. We show that the standard alanine scanning approach alone provided useful information about which AA positions in the peptide are important for TCR recognition, but its ability to elucidate cross-reactivity for the 7B5 TCR was limited. The 7B5 T-cell clone was isolated from a HLA-A*02:01 negative donor, thus due to the HLA-mismatched experimental setting, thymic selection did not occur. The 7B5 T-cell clone recognizes the hematopoietic restricted minor histocompatibility antigen (MiHA) HA-2 in the context of HLA-A*02:01. The 7B5 T-cell clone was shown to have a functional sensitivity that was similar to the patient derived T-cell clone HA2.27, as concentrations below 1nM of HA-2 peptide loaded on T2 cells could still trigger IFN- γ production. Also endogenously processed and presented HA-2 peptide was effectively recognized by the 7B5 T-cell clone, as indicated by IFN- γ production upon incubation with HA-2^{pos} EBV-LCLs and primary AML samples. Results were similar to the HA2.27 T-cell clone and no recognition of HA-2^{neg} EBV-LCLs or primary AML samples was observed.

The results of the alanine scanning approach suggested a low risk for broad cross-reactivity of the 7B5 T-cell clone, since exchanging the AAs for an alanine at positions 2, 3, 4, 5, 6 or 7 resulted in complete loss of peptide recognition. These results do not exclude the possibility of cross-reactivity towards other specific peptides, but it dismisses the risk of a highly promiscuous TCR. A search for specific human self-protein derived peptides with the motif X-I-G-E-V-L-V-X-X did not yield any potential off-target toxicity candidates. However, when we used the 9-mer CPL scan data to conduct a CPL-driven search of the human self-protein database, we found cross-reactivity directed against a peptide derived from the gene *CDH13*. This was confirmed by the ability of the 7B5 T-cell clone to recognize HA-2^{neg} EBV-LCLs transduced with the *CDH13*

gene and a range of tissues that endogenously express *CDH13* including fibroblasts, keratinocytes and proximal tubular epithelial cells (PTEC).

All these results demonstrate that the 7B5 T-cell clone can activate in response to healthy HLA-A*02:01^{POS} tissues such as fibroblasts, which is likely to have severe clinical consequences if this TCR was engineered into T-cells for adoptive therapy in patients. Therefore, we conclude that thorough validation of the specificity and characterization of cross-reactivity by combining several screening techniques should be a strict prerequisite for TCRs to be tested prior to their use in the clinic.

The alanine scanning approach was insufficient for detecting potentially dangerous cross-reactivities, whereas a CPL-driven search of the human self-protein database enabled the identification of a potentially dangerous reactivity directed towards a human self-protein derived epitope. In the alanine scanning approach only one AA is replaced at a time and the AAs are only replaced with a single AA (alanine), no other AAs with different properties. So it is no surprise that cross-reactivity against a peptide that differs from the MiHA peptide HA-2 in 5 AA positions, cannot be discovered using this assay. Because the 9-mer CPL fixes only one AA at one position per peptide mixture, all possible sequences (except those with more than one cysteine) are represented in the assay and cross-reactive peptides that differ substantially from the immunogenic target peptide can be identified. The downside of this approach is that every mixture consists of many peptides, lowering the concentration per unique peptide and increasing the competition for HLA-binding within every mixture. These factors might influence the results and could explain why for some T-cell clones that we tested with the 9-mer CPL, a sufficient peptide recognition signature could not be determined (data not shown). Also, the 9-mer CPL-driven search of the human self-protein database produces such a great number of potential

candidates that a selection strategy is needed to keep further screening experiments manageable, risking unwanted exclusion of the target peptides you're searching for.

Although the 7B5 T-cell clone, which is derived from a HLA-mismatched setting, showed a potentially dangerous cross-reactivity, this does not mean that all TCRs from an allogeneic setting are of lesser clinical interest compared to clones derived from HLA-matched settings, e.g. the patient derived T-cell clone HA2.27. All TCRs have an intrinsic cross-reactive capacity²⁶, which is necessary to cover all naturally occurring antigens that may be encountered²⁷. Thus, the relevant question is not whether a TCR is cross-reactive, but how to predict the clinical consequences of this cross-reactivity²⁸. Therefore, thorough screening for off-target toxicity must be included in the preclinical phases, to determine whether a TCR is safe for clinical application via adoptive transfer of TCR-engineered T-cells. To further reduce potential risks, the use of a so called 'suicide switch' could also be considered²⁹, which enables immediate elimination of the transfused T-cells upon signs of toxicity.

In summary, we demonstrate that a standard alanine scanning approach provided useful information about which positions in the peptide sequence are important for TCR recognition, but it did not predict off-target reactivity of the 7B5 TCR. However, we were able to detect off-target reactivity directed against a peptide derived from *CDH13* using a CPL-driven search of the human self-protein database, which was confirmed using *CDH13* transduced HA-2^{neg} EBV-LCLs and screening against several different cell subsets which endogenously express *CDH13*. This example demonstrates the advantage and need of combining several screening techniques to characterize the cross-reactivity and specificity of TCRs.

Materials and Methods

Culture conditions and cells

All studies using human material were approved by the Leiden University Medical Center ethical review board. Peripheral blood was obtained from healthy individuals or patients after informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-gradient centrifugation.

T-cells were cultured in T-cell medium consisting of IMDM (Lonza) supplemented with 100 IU/ml IL-2 (Proleukine; Novartis Pharma), 5% fetal bovine serum (FBS; Gibco, Life Technologies), 5% human serum, 2 mM L-glutamine (Lonza) and 1% penicillin/streptomycin (Lonza). T-cells were stimulated using irradiated feeders in a 1:5 ratio in T-cell medium supplemented with 0.8 µg/ml phytohemagglutinin (PHA; Biochrom AG) 8-16 days prior to experiments.

Epstein-Barr virus -transformed B-lymphoblastic cell lines (EBV-LCLs) were generated using standard procedures and cultured in IMDM supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin.

Primary AML samples from patients at time of diagnosis were thawed and cultured overnight in IMDM supplemented with 10% FCS before use in experiments.

Fibroblasts, keratinocytes and other non-hematopoietic cell subsets were cultured either in the absence or presence of 200 IU/ml IFN-γ for two days and washed twice before use in experiments.

Isolation of the HA-2 reactive T-cell clone 7B5

To isolate HA-2 reactive T-cell clones, 500×10^6 PBMCs from an HLA-A*02:01^{neg} healthy donor were incubated with PE-labeled pMHC-tetramers, composed of HA-2 9-mer peptide

(YIGEVLVSV) bound in HLA-A*02:01, for 1 hour at 4°C. Cells were washed twice, and incubated with anti-PE-microbeads (Miltenyi Biotec) for 15 minutes at 4°C. PE-labeled cells were isolated on an LS column (Miltenyi Biotec) according to manufacturer's instruction. Positively selected cells were stained with an anti-CD8 Alexa700-labelled antibody (Invitrogen/Caltag) in combination with FITC-conjugated antibodies against CD4, CD14, and CD19 (BD Pharmingen). pMHC-tetramer^{pos} CD8^{pos} FITC^{neg} T-cells were single-cell sorted into round-bottom 96-well plates containing 5×10^4 irradiated feeders in 100 μ l T-cell medium supplemented with 0.8 μ g/ml PHA for expansion.

FACS analysis

FACS acquisition was performed on a LSRII (BD Biosciences) and was analyzed using Diva Software (BD Biosciences). T-cell clones were analyzed for binding to the HA-2 specific APC-labeled pMHC-tetramer, an irrelevant PE-labeled pMHC-tetramer and an Alexa700-conjugated antibody against CD8 (Invitrogen/Caltag). 10,000 T-cells were first incubated with 2 μ g/ml pMHC-tetramers for 15 min at 37°C and washed, before anti-CD8 antibodies were added and incubated for an additional 15 min at 4°C.

Functional analysis

For analysis of IFN- γ production, 5000 T-cells were cocultured with 30,000 target cells or T2 cells loaded with peptides in 384 well plates. Peptide loading was performed by incubating T2 cells for 30 minutes at 37°C and 5% CO². T-cells were washed twice before use. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA (Sanquin Reagents).

To assess the peptide recognition signature we used a previously described 9-mer CPL scan²², consisting of 180 different peptide mixtures. In each peptide mixture all peptides have one fixed L-amino acid (AA) residue at one AA position, but all other positions are degenerate, enabling incorporation of any 1 of 19 natural L-amino acids in all remaining 8 positions (cysteine is excluded in non-fixed positions). For this assay, we pulsed 20,000 T2 cells with each of the 180 different peptide mixtures at a concentration of 100 μ M for two hours at 37°C and 5% CO² in 40 μ l T-cell medium (IMDM supplemented with 100 IU/ml IL-2, 5% fetal bovine serum, 5% human serum, 2 mM L-glutamine and 1% penicillin/streptomycin). After peptide loading, 4000 T-cells in 20 μ l T-cell medium were added per well. After overnight incubation, supernatants were harvested and IFN- γ production was measured by ELISA (Sanquin Reagents).

Analysis of the peptide recognition signature

To analyze the data from the 9-mer CPL scan, we used the WSBC PI CPL webtool³⁰ that applies a mathematical strategy to match the peptide recognition signature³¹ with the human proteome to predict the most likely human self-protein derived peptide sequences that might be recognized by the tested TCR²⁶. We examined 100 peptides with the best log likelihood scores and removed duplicate sequences. The 10 peptide sequences that were predicted to bind HLA-A*02:01, according to NetMHC4.0, were synthesized.

Gene transduction

The *CDH13* gene was cloned into the modified MP71-retroviral backbone, together with the truncated nerve growth factor-receptor (NGF-R, also known as CD271). The constructs were transfected into Phoenix-A cells using helper vector M57 and Fugene HD reagent (Roche). Virus

supernatant was harvested after 48 and 72 hours and stored at -80°C.

For transduction of EBV-LCLs, 24-well non tissue-culture plates were coated with 30 mg/ml retronectin (Takara) for 2 hours at room temperature and blocked with 2% human serum albumin (Sanquin Reagents) for 30 minutes. Viral supernatant was thawed, then 500 µl per well was added to the 24-well plate and spun down at 2000 G for 20 minutes at 4°C. 100,000 EBV-LCLs per well were added in 500 µl fresh IMDM supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin and incubated overnight at 37°C and 5% CO². *CDH13*^{pos} EBV-LCLs were MACS purified using anti-CD271 PE-labeled antibody (BD Pharmingen) and anti-PE-microbeads (Miltenyi Biotec). *CDH13* transduced cells were isolated on an LS column following manufacturer's instructions.

Acknowledgements

This research was supported by the Landsteiner Foundation for Blood Transfusion Research, grant no. LSBR1331. We thank Marieke Griffioen for sharing the microarray gene expression database. The authors disclose no potential conflicts of interest.

Author Contributions

H.M.B. designed the experiments, performed experiments, analyzed the data and wrote the manuscript.

D.M.S. performed 9-mer CPL scan.

A.W. performed experiments.

R.S.H. prepared the virus supernatants.

L.W. provided the 9-mer CPL and reviewed and edited the manuscript.

J.H.F.F reviewed and edited the manuscript.

M.H.M.H. acquired the funding, supervised the research and reviewed and edited the manuscript.

References

1. Holzinger, A, Barden, M, and Abken, H (2016). The growing world of CAR T cell trials: a systematic review. *Cancer immunology, immunotherapy : CII* **65**: 1433-1450.
2. Rosenberg, SA, and Dudley, ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. *Current opinion in immunology* **21**: 233-240.
3. Besser, MJ, Shapira-Frommer, R, and Schachter, J (2015). Tumor-Infiltrating Lymphocytes: Clinical Experience. *Cancer journal (Sudbury, Mass)* **21**: 465-469.
4. Thomas, S, Stauss, HJ, and Morris, EC (2010). Molecular immunology lessons from therapeutic T-cell receptor gene transfer. *Immunology* **129**: 170-177.
5. Stromnes, IM, Schmitt, TM, Chapuis, AG, Hingorani, SR, and Greenberg, PD (2014). Re-adapting T cells for cancer therapy: from mouse models to clinical trials. *Immunological reviews* **257**: 145-164.
6. Robbins, PF, Kassim, SH, Tran, TL, Crystal, JS, Morgan, RA, Feldman, SA, *et al.* (2015). A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Nature medicine* **21**: 1019-1027.
7. Rapoport, AP, Stadtmauer, EA, Binder-Scholl, GK, Goloubeva, O, Vogl, DT, Lacey, SF, *et al.* (2015). NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma **21**: 914-921.
8. Kageyama, S, Ikeda, H, Miyahara, Y, Imai, N, Ishihara, M, Saito, K, *et al.* (2015). Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **21**: 2268-2277.
9. Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS, *et al.* (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* **114**: 535-546.
10. Palmer, E (2003). Negative selection--clearing out the bad apples from the T-cell repertoire. *Nature reviews Immunology* **3**: 383-391.
11. Kunert, A, Obenaus, M, Lamers, CHJ, Blankenstein, T, and Debets, R (2017). T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk. *Clinical cancer research : an official journal of the American Association for Cancer Research* **23**: 6012-6020.
12. Linette, GP, Stadtmauer, EA, Maus, MV, Rapoport, AP, Levine, BL, Emery, L, *et al.* (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* **122**: 863-871.
13. Stone, JD, Harris, DT, and Kranz, DM (2015). TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. *Current opinion in immunology* **33**: 16-22.
14. Stone, JD, and Kranz, DM (2013). Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. *Frontiers in immunology* **4**: 244.
15. Morgan, RA, Chinnasamy, N, Abate-Daga, D, Gros, A, Robbins, PF, Zheng, Z, *et al.* (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. *Journal of immunotherapy (Hagerstown, Md : 1997)* **36**: 133-151.
16. van den Berg, JH, Gomez-Eerland, R, van de Wiel, B, Hulshoff, L, van den Broek, D, Bins, A, *et al.* (2015). Case Report of a Fatal Serious Adverse Event Upon

- Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. *Molecular therapy : the journal of the American Society of Gene Therapy* **23**: 1541-1550.
17. Raman, MC, Rizkallah, PJ, Simmons, R, Donnellan, Z, Dukes, J, Bossi, G, *et al.* (2016). Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. *Scientific reports* **6**: 18851.
 18. Jahn, L, van der Steen, DM, Hagedoorn, RS, Hombrink, P, Kester, MG, Schoonakker, MP, *et al.* (2016). Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. *Oncotarget* **7**: 77021-77037.
 19. Voogt, PJ, Goulmy, E, Veenhof, WF, Hamilton, M, Fibbe, WE, Van Rood, JJ, *et al.* (1988). Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. *The Journal of experimental medicine* **168**: 2337-2347.
 20. Goulmy, E (1996). Human minor histocompatibility antigens. *Current opinion in immunology* **8**: 75-81.
 21. Hickman, ES, Lomax, ME, and Jakobsen, BK (2016). Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. *Journal of biomolecular screening* **21**: 769-785.
 22. Wooldridge, L, Laugel, B, Ekeruche, J, Clement, M, van den Berg, HA, Price, DA, *et al.* (2010). CD8 controls T cell cross-reactivity. *Journal of immunology (Baltimore, Md : 1950)* **185**: 4625-4632.
 23. Heemskerk, MH, Hoogeboom, M, de Paus, RA, Kester, MG, van der Hoorn, MA, Goulmy, E, *et al.* (2003). Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* **102**: 3530-3540.
 24. Marijt, WA, Heemskerk, MH, Kloosterboer, FM, Goulmy, E, Kester, MG, van der Hoorn, MA, *et al.* (2003). Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proceedings of the National Academy of Sciences of the United States of America* **100**: 2742-2747.
 25. Pont, MJ, Honders, MW, Kremer, AN, van Kooten, C, Out, C, Hiemstra, PS, *et al.* (2016). Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. *PloS one* **11**: e0155165.
 26. Wooldridge, L, Ekeruche-Makinde, J, van den Berg, HA, Skowera, A, Miles, JJ, Tan, MP, *et al.* (2012). A single autoimmune T cell receptor recognizes more than a million different peptides. *The Journal of biological chemistry* **287**: 1168-1177.
 27. Degauque, N, Brouard, S, and Soullillou, JP (2016). Cross-Reactivity of TCR Repertoire: Current Concepts, Challenges, and Implication for Allotransplantation. *Frontiers in immunology* **7**: 89.
 28. Singh, NK, Riley, TP, Baker, SCB, Borrman, T, Weng, Z, and Baker, BM (2017). Emerging Concepts in TCR Specificity: Rationalizing and (Maybe) Predicting Outcomes. *Journal of immunology (Baltimore, Md : 1950)* **199**: 2203-2213.

29. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C, *et al.* (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. *The New England journal of medicine* **365**: 1673-1683.
30. Szomolay, B, Liu, J, Brown, PE, Miles, JJ, Clement, M, Llewellyn-Lacey, S, *et al.* (2016). Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors. *Immunology and cell biology* **94**: 573-582.
31. Wooldridge, L (2013). Individual MHCI-Restricted T-Cell Receptors are Characterized by a Unique Peptide Recognition Signature. *Frontiers in immunology* **4**: 199.

Table 1: HLA-A*02:01 binding properties of the peptides used for the amino acid scanning approach.

Sequence	netMHC4.0 (nM; binding level)
YIGEVLVSV	7.0; SB
YIGEVLVSM	57.7; WB
AIGEVLVSV	33.4; SB
YAGEVLVSV	41.6; WB
YIAEVLVSV	3.3; SB
YIGAVLVSV	12.9; SB
YIGEALVSV	7.6; SB
YIGEVAVSV	14.9; SB
YIGEVLASV	7.1; SB
YIGEVLVAV	9.1; SB
YIGEVLVSA	30.6; SB

Table 2: Selected potential cross-reactive human self-protein derived peptide targets of the 7B5 T-cell clone. The peptides in this table are selected based on their predicted recognition by the 7B5 TCR according to a CPL-driven search of the human self-protein database conducted using the WSBC PI CPL webtool, and subsequently filtered based on their ability to bind HLA-A*02:01 as predicted by NetMHC4.0. Peptides are ordered based on their predicted likelihood of recognition.

Peptide number	Peptide sequence	AA difference	netMHC4.0 (nM; binding level)	Gene	Protein accession
p01	SVGSVLLTV	5	160.5; WB	<i>CDH13</i>	NP_001207417
p02	YIGEVLVSV	-	7.0; SB	<i>MYO1G</i>	NP_149043
p03	FVGEDLVTI	5	42.6; WB	<i>BACE2</i>	NP_036237
p04	YIGENILVL	5	48.7; WB	<i>ASIC1</i>	NP_001086
p05	TLQEVLLTV	5	11.8; SB	<i>GZMH</i>	NP_219491
p06	FIGEVVSV	2	8.1; SB	<i>MYO1D</i>	NP_056009
p07	SVGEVLQSV	3	116.2; WB	<i>AKAP3</i>	NP_006413
p08	YIGQVLVTA	3	253.2; WB	<i>EML5</i>	NP_899243
p09	AQGEVQLTV	5	144.1; WB	<i>PLXNB2</i>	NP_036533
p10	TLGNVLVTV	4	26.7; SB	<i>EXOC1</i>	NP_001020095

Legends

Figure 1: The 7B5 T-cell clone exhibits similar sensitivity to HA-2 compared to clone HA2.27 in a peptide stimulation assay and pMHC-tetramer staining. (A) T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with T2 cells (30.000/well) loaded with HA-2 peptide at different concentrations. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. (B) T-cell clones were analyzed for binding to specific APC-labeled pMHC-tetramers. Depicted dotplots are gated for CD8^{pos} lymphocytes.

Figure 2: The 7B5 T-cell clone recognizes HA-2 expressing EBV-LCLs and primary AML samples. (A) T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with several EBV-LCLs at a stimulator to responder (S:R) ratio of 6:1. Controls included EBV-LCLs from the patient (LCL MRJ, HLA-A*02:01^{pos} HA-2^{pos}) and donor (LCL IZA, HLA-A*02:01^{pos} HA-2^{neg}) we isolated T-cell clone HA2.27 from, as well as HLA-A*02:01^{neg} controls LCL-MSF and LCL-PSU. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. Depicted values are the average of duplicate measurements \pm SD. (B) T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with HLA-A*02:01^{pos} HA-2^{neg} primary AML sample (AML1), HLA-A*02:01^{pos} HA-2^{pos} primary AML samples (AML2,-3,-4), and HLA-A*02:01^{pos} HA-2^{neg} fibroblasts (FB) and keratinocytes (KC) at an S:R ratio of 6:1. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. Depicted values are the average of duplicate measurements \pm SD.

Figure 3: The alanine scanning approach for T-cell clones 7B5 and HA2.27. T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with T2 cells (30.000/well), loaded with 8 nM (A), 40 nM (B) and 200 nM (C) peptides. After overnight incubation IFN- γ concentrations were measured in the supernatant by ELISA. Where alanine substitution resulted in a substantial decrease in IFN- γ production compared to the immunogenic HA-2 sequence, the residue at this position was considered essential.

Figure 4: A heatmap representation of a 9-mer CPL scan of the 7B5 T-cell clone. A heatmap depicting the intensity of IFN- γ production by the 7B5 T-cell clone (4.000/well) in response to T2 cells (20.000/well) loaded with the 180 peptide mixtures in a 9-mer CPL scan, indicating which AAs are preferentially recognized at certain positions in the peptide sequence. CPL scan data are normalized in each row so that the values range from high (red) to low (blue); the maximum intensity is the largest of all red values in the rows. Amino acids are grouped according to their physicochemical properties as follows: polar, uncharged amines: Q, N; polar, uncharged alcohols: T, S; small: G, A, C; hydrophobic: A–H; aliphatic: V, I, L; aromatic: Y, F, W, H; large: F, W; charged basic: H, K, R; and charged acidic: E, D.

Figure 5: The 7B5 T-cell clone recognizes the *CDH13* derived peptide p01, whereas T-cell clone HA2.27 does not. T-cell clones (A) 7B5 and (B) HA2.27 (5.000/well) were cocultured with T2 cells (30.000) loaded with the selected peptides at different concentrations. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. Depicted values are the average of duplicate measurements \pm SD. p01: Cadherin-13 isoform 2; p02: Myosin-Ig MiHA HA-2 (V); p03: Beta-secretase 2 Isoform 4; p04: Amiloride-

sensitive cation channel 2, neuronal isoform b; p05: Granzyme H; p06: Myosin-Id; p07: A-kinase anchor protein 3; p08: Echinoderm microtubule-associated protein-like 5; p09: Plexin-B2 precursor; p10: Exocyst complex component 1 isoform 1; p11: Myosin-Ig AC HA-2 (M). (C) T-cell clone 7B5 and HA-2 control clone (5.000/well) were cocultured with HA-2^{neg} EBV-LCL IZA and HRK, untransduced or transduced with *CDH13*, at an S:R ratio of 6:1. The HA-2^{pos} EBV-LCL MRJ was included as a positive control. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. Depicted values are the average of duplicate measurements \pm SD.

Figure 6: The endogenously processed *CDH13* derived peptide p01, presented in HLA-A*02:01, efficiently activates the 7B5 T-cell clone, but not T-cell clone HA2.27. T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with different cell subsets endogenously expressing the *CDH13* gene: keratinocytes and fibroblasts, untreated or pretreated with IFN- γ for 2 days to upregulate HLA expression, proximal tubular epithelial cells, and melanoma cell line FM6. To confirm that only HLA-A*02:01 restricted epitopes are recognized, we tested the 7B5 and HA2.27 T-cell clone also against HLA-A*02:01^{neg} fibroblasts, untreated or pretreated with IFN- γ . We also included the EBV-LCL controls from the patient (LCL MRJ, HLA-A*02:01^{pos} HA-2^{pos}) and donor (LCL IZA, HLA-A*02:01^{pos} HA-2^{neg}) we isolated the HA2.27 T-cell clone from. After overnight incubation, supernatants were harvested, and the concentration of IFN- γ was measured by ELISA. Average IFN- γ production by the HA2.27 T-cell clone stimulated with LCL MRJ was set to 1. Depicted values are the average of duplicate measurements \pm SD.

*Single measurements.

Supplementary Figure 1: Gene expression profile for minor histocompatibility antigen HA-2 (MYO1G). Probe fluorescence intensity is shown on the x-axis in logarithmic scale. On the y-axis malignant and healthy (non-)hematopoietic cell types are shown. Each dot represents a different sample and the mean and standard deviation of gene expression is shown for each cell type.

Supplementary Table 1: Potential cross-reactive human self-protein derived peptide targets of the 7B5 T-cell clone. The peptides in this table are selected based on their predicted recognition by the 7B5 T-cell clone according to a CPL-driven search of the human self-protein database conducted using the WSBC PI CPL webtool.

Supplementary Figure 2: Gene expression profile for *CDH13*. Probe fluorescence intensity is shown on the x-axis in logarithmic scale. On the y-axis malignant and healthy (non-)hematopoietic cell types are shown. Each dot represents a different sample and the mean and standard deviation of gene expression is shown for each cell type.







Figure 1

A



HA-2 peptide	-	+	+	+	+	+	-
HLA-A*02:01	+	+	+	+	-	-	-

B



HA-2 peptide	-	+	-	+	+	+	-	-
HLA-A*02:01	+	+	+	+	+	+	+	-

Figure 2




Figure 3




Figure 4





Figure 5



CDH13 peptide	-	-	+	+	+	+	+	+	+	+	+	+	+	+	-
HA-2 peptide	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
HLA-A*02:01	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-

Figure 6